In an adult with type 2 diabetes on liraglutide (Victoza) 1.2 mg daily, insulin glargine (Lantus) 20 U nightly, and an insulin‑to‑carbohydrate ratio of 1 U per 10 g, with fasting glucose ~314 mg/dL and 301 mg/dL, how much should the basal insulin be increased and how should the insulin‑to‑carbohydrate ratio be adjusted?

Immediate Basal Insulin Escalation and Insulin‑to‑Carbohydrate Ratio Adjustment

Increase Lantus by 4 units every 3 days until fasting glucose consistently reaches 80–130 mg/dL, and maintain the current 1:10 insulin‑to‑carbohydrate ratio while optimizing basal coverage before making any prandial adjustments. 1

Basal Insulin (Lantus) Titration Protocol

• Aggressive basal escalation is required: With fasting glucose values of 314 mg/dL and 301 mg/dL (both ≥180 mg/dL), increase Lantus by 4 units every 3 days until fasting glucose reaches the target range of 80–130 mg/dL. 1
• The current 20‑unit dose is profoundly inadequate for these fasting glucose levels; systematic titration should bring values into target within 2–3 weeks. 2
• If fasting glucose drops to 140–179 mg/dL during titration, reduce the increment to 2 units every 3 days. 1
• Critical safety threshold: If any glucose reading falls below 70 mg/dL, immediately reduce the basal dose by 10–20 % before the next administration. 1

When to Stop Basal Escalation (Avoiding Over‑Basalization)

• Cease further basal increases when the dose approaches 0.5 units/kg/day (approximately 35–40 units for most adults) without achieving fasting glucose targets. 1, 2
• At this threshold, add prandial insulin rather than continuing basal escalation to prevent "over‑basalization." 1
• Clinical signs of over‑basalization include: basal dose >0.5 units/kg/day, bedtime‑to‑morning glucose differential ≥50 mg/dL, hypoglycemia episodes despite overall hyperglycemia, and high glucose variability. 1, 2

Insulin‑to‑Carbohydrate Ratio (ICR) Management

• Do not adjust the 1:10 ratio yet: The current ICR of 1 unit per 10 g carbohydrate is an appropriate starting point and should be maintained while basal insulin is being optimized. 2
• Adjust the ICR only if 2‑hour post‑prandial glucose values consistently exceed 180 mg/dL after at least three days of observation at the current ratio. 2
• If post‑prandial glucose remains >180 mg/dL after basal optimization, consider tightening the ICR to 1 unit per 8 g carbohydrate or adding scheduled prandial insulin. 2
• The fasting hyperglycemia (314 and 301 mg/dL) indicates inadequate basal coverage, not insufficient prandial insulin; fix the basal component first. 1

Monitoring Requirements During Titration

• Daily fasting glucose checks are essential to guide basal dose adjustments every 3 days. 1, 2
• Check pre‑meal glucose before each meal to calculate any needed correction doses. 2
• Obtain 2‑hour post‑prandial glucose after meals to assess ICR adequacy once basal insulin is optimized. 2
• Reassess the insulin regimen every 3 days during active titration. 2
• Measure HbA1c every 3 months until stable glycemic control is achieved. 2

Role of Liraglutide (Victoza) 1.2 mg

• The recent increase to 1.2 mg liraglutide is appropriate; this dose typically reduces HbA1c by approximately 1.0–1.2 % when added to existing therapy. 3, 4
• Liraglutide provides glucose‑dependent insulin secretion, glucagon suppression, and delayed gastric emptying, complementing basal insulin therapy. 3
• The combination of optimized basal insulin, liraglutide 1.2 mg daily, and metformin can achieve HbA1c reductions of 2–3 % over 3–6 months. 2
• Liraglutide also promotes moderate weight loss (1.5–4.0 kg) and mild blood pressure reduction, beneficial effects beyond glycemic control. 3, 5, 6
• Gastrointestinal side effects (nausea, vomiting) may occur initially but usually diminish with time and rarely require discontinuation. 3, 4

Metformin Optimization

• Continue metformin at the maximum tolerated dose (up to 2,000–2,550 mg daily) when intensifying insulin therapy. 2
• Metformin reduces total insulin requirements by 20–30 % and yields superior glycemic control compared with insulin alone. 2
• Do not discontinue metformin when adding or intensifying insulin unless contraindicated. 2

When to Add Scheduled Prandial Insulin

• Add prandial insulin when basal insulin reaches ≈0.5 units/kg/day (35–40 units) without achieving fasting glucose targets, or when HbA1c remains above goal after 3–6 months of optimized basal therapy. 2
• Initiate prandial insulin with 4 units of rapid‑acting insulin before the largest meal, or use 10 % of the current basal dose as the starting prandial amount. 2
• Administer prandial insulin 0–15 minutes before meals for optimal post‑prandial control. 2
• Titrate each meal dose by 1–2 units every 3 days based on 2‑hour post‑prandial glucose, targeting <180 mg/dL. 2

Expected Clinical Outcomes

• Aggressive basal titration (4‑unit increments every 3 days for fasting glucose ≥180 mg/dL) should bring fasting glucose into the 80–130 mg/dL range within 2–3 weeks. 2
• Approximately 68 % of patients achieve mean glucose <140 mg/dL with properly implemented basal‑bolus therapy, compared with 38 % using inadequate regimens. 1
• Systematic basal titration, when performed as recommended, does not increase hypoglycemia risk. 2

Hypoglycemia Management

• Treat glucose <70 mg/dL immediately with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if necessary. 2
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 1, 2
• Avoid using rapid‑acting insulin at bedtime as a sole correction dose, as this markedly increases nocturnal hypoglycemia risk. 2

Common Pitfalls to Avoid

• Do not delay basal dose escalation when fasting glucose consistently exceeds 180 mg/dL; prolonged hyperglycemia raises complication risk. 1
• Do not adjust the ICR based on fasting hyperglycemia; fasting glucose reflects basal insulin adequacy, not carbohydrate coverage. 1
• Avoid continuing basal escalation beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia, as this leads to over‑basalization and higher hypoglycemia risk. 1, 2
• Do not discontinue metformin during insulin intensification unless contraindicated, as omission increases insulin needs and worsens outcomes. 2